Last updated: June 6, 2026
Executive summary: Multiple U.S.-market suppliers produce potassium chloride (KCl) 40 mEq products, including immediate-release tablets/capsules and oral solutions, with sourcing commonly fragmented by dosage form and strength presentation. Supplier selection for procurement and substitution risk typically turns on FDA label form, strength unit (40 mEq equivalent), and whether the product is generic vs brand.
Who supplies potassium chloride 40 mEq in the US market?
Answer: Potassium chloride 40 mEq is supplied by a range of generic manufacturers and label-specific repackagers/wholesalers, with actual sourcing dependent on the exact dosage form (tablet, capsule, extended-release, or oral solution) and the product label strength expression in mEq.
Key supplier categories
- FDA-listed manufacturers of the finished dosage form (tablets, capsules, powders/granules, and oral solutions).
- Contract manufacturers that produce under label/brand arrangements.
- Distributors and re-packers that supply wholesalers, but do not always own the FDA manufacturing record.
Procurement reality for “40 mEq”
“40 mEq” is a strength target, not a single drug substance. Many products are marketed as potassium chloride tablets where the label shows the potassium content in mEq. That means:
- Two products can both be “potassium chloride 40 mEq” but differ in inactive ingredients, release profile, and unit count per bottle, which affects therapeutic interchangeability and procurement compatibility.
What dosage forms of potassium chloride 40 mEq are available from suppliers?
Answer: Suppliers typically offer potassium chloride as oral solid dosage forms (tablets or capsules) and oral liquid/solution, with different release profiles. For “40 mEq,” the most common procurement match is an oral immediate-release tablet/capsule strength expressed as potassium content.
Common dosage forms
- Immediate-release oral tablets/capsules
- Oral extended-release tablets (less likely to match “40 mEq” packaging conventions, but still appears in certain labels)
- Oral solutions
Why dosage form matters for sourcing
- IR vs ER changes dissolution rate and potentially substitution decisions for inpatient dosing.
- Many pharmacy systems treat IR and ER as non-interchangeable even when both are potassium chloride and both use mEq labeling.
Which companies manufacture generic potassium chloride mEq products?
Answer: Potassium chloride oral mEq products are widely manufactured by U.S. generics companies and global API-to-finished companies that support oral solids and liquids.
Supplier selection factors
For procurement and substitution, buyers typically screen suppliers on:
- FDA product label (release profile and formulation)
- Current Good Manufacturing Practice (cGMP) record and recent FDA inspections
- Batch reliability and fill rate
- Distribution footprint and lot traceability
Competitive procurement issue
KCl tends to have high supply breadth, but shortages still occur due to:
- constrained tablet/capsule capacity,
- ingredient supply variability,
- or quality actions impacting specific lots.
What is the Orange Book status of potassium chloride 40 mEq?
Answer: Potassium chloride products generally have multiple generic listings across dosage forms, but the exact Orange Book status depends on the specific finished dosage form and release profile. Many KCl strengths and presentations have limited patent barriers compared with branded specialty drugs.
How to interpret “Orange Book” for KCl mEq products
- For high-volume electrolyte products, patent estates are often narrower and coverage may be limited to:
- specific formulation improvements,
- specific manufacturing methods,
- or specific label claims.
- As a result, market access often occurs through generic entries rather than long exclusivity blocks.
Do potassium chloride 40 mEq suppliers face patent or litigation constraints?
Answer: In most cases for KCl oral mEq products, the market is dominated by established generics and patent constraints are less likely to be the gating factor than for newer therapies. Litigation risk typically concentrates on:
- specific formulations (if any are protected),
- specific manufacturing processes,
- or label-specific exclusivity if tied to data exclusivity rather than patents.
Where litigation typically appears
- Paragraph IV challenges are usually tied to a specific listed patent for a specific NDA/ANDA product.
- For KCl, where patent estates are modest, repeat filings or challenges can still occur but do not often represent a long delay to generic availability.
What generic entry risks exist for potassium chloride 40 mEq?
Answer: Generic entry risk is typically lower than for complex biologics or specialty small molecules, but practical risks exist:
- limited supplier capacity,
- drug substance sourcing volatility,
- and quality events that temporarily remove specific lots from distribution.
Risk triggers for shortages
- single-source manufacturing sites,
- supplier transition events,
- component shortages (excipients, coating systems, packaging),
- or FDA quality actions that affect shelf stock.
How can purchasers verify that a potassium chloride 40 mEq supplier product is truly equivalent?
Answer: Buyers should verify equivalence using label and formulation controls, not just the “mEq” figure.
Core verification checklist
- Dosage form and release (IR vs ER)
- Strength expression: “40 mEq” per tablet/capsule and total mEq per unit
- Label instructions (frequency, max daily dose limits)
- Inactive ingredients that may matter for excipient sensitivities
- NDAs/ANDAs and labeler/manufacturer on the package
Which distributors supply potassium chloride 40 mEq to hospitals and pharmacies?
Answer: Large U.S. pharmaceutical distributors supply KCl products widely through wholesaling channels, with item availability tied to the specific NDA/ANDA.
Common procurement channel patterns
- Direct-to-wholesaler from generic manufacturers
- Distributor-sourced allocations during supply constraints
- Repackaging for market-specific presentations (less common for strict 40 mEq tablet/capsule formats)
How does international sourcing affect potassium chloride 40 mEq availability?
Answer: International supply can help cover demand when U.S. capacity tightens, but buyers face added controls:
- documentation and traceability,
- import lot release cadence,
- and potential variability in excipients and tablet/capsule physical attributes.
Regulatory gate
U.S. supply depends on FDA compliance for imported finished dosage forms and manufacturing sites.
Key takeaways
- Potassium chloride 40 mEq is supplied through multiple generic and label-specific sources, with availability driven by dosage form and release profile, not just strength.
- Supplier procurement should be based on label equivalence and NDAs/ANDAs, since “mEq” targets can mask IR/ER and formulation differences.
- Patent-driven market blocking is typically less central for KCl oral mEq products; supply reliability and quality/lot availability often matter more for continuity of supply.
- For hospital formularies and pharmacy substitution programs, the safest approach is to anchor purchasing to the specific labeled product (manufacturer/labeler) rather than relying on the mEq number alone.
FAQs
1) Are potassium chloride 40 mEq tablets interchangeable with potassium chloride 40 mEq capsules?
Labeling must be checked for dosage form, release, and formulation. “mEq strength” alone does not guarantee substitution.
2) Can potassium chloride 40 mEq extended-release products replace immediate-release versions?
No, IR and ER are typically treated as non-interchangeable due to release profile differences.
3) What causes intermittent potassium chloride shortages despite many suppliers?
Lot-level quality events, limited tablet/capsule capacity at specific sites, ingredient/excipient constraints, and FDA actions affecting specific presentations.
4) How do I confirm the correct potassium content when switching brands of KCl 40 mEq?
Verify the label states “40 mEq” per tablet/capsule and confirm the total mEq per unit dose and dosing instructions.
5) What is the fastest way to stabilize supply for potassium chloride 40 mEq?
Use a multi-NDA sourcing strategy aligned to your formulation and release requirements, and pre-approve alternates based on label equivalence.
References (APA)
No sources were provided in the prompt, and no verifiable supplier roster or product-label-specific citations are available to cite accurately.
